The explosion in genetic and biological information presents an opportunity to explore, and ultimately exploit for health benefits, the inter-individual differences in the body's ability to metabolise, and respond to, nutrients. This has led to the concept of personalised nutrition as opposed to public health nutrition-the 'holy grail' of individualised dietary recommendations for optimal health. Using examples from micronutrient and lipid metabolism, this article assesses the scientific progress in our understanding of genetic influences on nutrition and its impact on risk of multifactorial diseases, and identifies the implications of research to date. Genetic variants that influence nutrient metabolism have been identified, but individual variants have not been conclusively linked to the risk of multifactorial diseases such as cancer and cardiovascular disease. Increasingly, it is realised that multiple variants influence nutrient metabolism and health outcomes. There is a need for quantitative assessment and mathematical modelling of multiple genetic effects. It is likely that personalised nutrition will not have the dramatic impact that was once expounded but will in the future, as we understand the complex influences of genetics, and impinge on the work of medical practitioners and dietitians by improving their ability to provide individual dietary advice and by contributing to the development of biomarkers.
INTRODUCTION
Consider the following scenario: a health-conscious young man in his mid-thirties has given a DNA sample and paid for his genome to be sequenced by an approved 'personalised genomics' service company; he wants to reduce his risk of diseases in older age and has heard about nutrigenomics, but what does he do (see Figure 1 )?
He considers asking the service company to list the genetic variants that affect disease risk and nutrient metabolism, to identify the variants which he carries, and to provide lifestyle advice. He considers taking the information to his general practitioner/ local hospital by whom the information is sent to a Health Service Bioinformatics Department where the allelic variants that affect disease risk and nutrient metabolism are identified, and then a clinical nutritionist/biochemist gives nutritional and lifestyle advice. He considers consulting a nutritionist trained in using genetic information in relation to dietary advice. S(he) uses publically available bioinformatic software to combine dietary and genome sequence information to predict his disease risk and gives him dietary and lifestyle advice. He considers that the feedback will cause unnecessary health concerns and that there will be negative effects on third parties such as employers and insurance companies, so he does not use the information.
This scenario represents a futuristic picture of personalised nutrition 1 in which (a) either medical practitioners, nutritionists or dietitians take sophisticated genetic information into account before deciding on nutritional advice to reduce disease risk and optimise health, or (b) individuals pay commercial enterprises for advice on the basis of such genetic information. Despite the increase in knowledge of how genetics influence nutrient metabolism these possibilities are at present 'science fiction'. In this article I will use selected examples to illustrate how far nutrigenomics, the science behind the concept of personalised nutrition, has travelled along the road towards these goals; the chosen examples, many related to micronutrients, are an eclectic mixture based largely on my personal interests, and are not intended to be comprehensive.
THE CONCEPT OF PERSONALISED NUTRITION
The sequencing of the human genome has led to the rapid development of high-throughout methods for assessing genomewide patterns of gene expression and genome-wide genetic variations. It is now possible to characterise the expression of the huge number of stable genetic variants, such as single-nucleotide polymorphisms (SNPs), in individuals within the human population. The subsequent rapid fall in sequencing costs, together with the development of technologies to assess large numbers of SNPs, including genome-wide association studies (GWAS), has revolutionised approaches to study genetic influences on disease risk. Large research collaborations such as the Personal Genome Project, the International HapMap consortium and the Human Variome Project have been initiated to gather information on genetic variation with the ultimate aims of linking genetic variation to human disease risk and promoting the development of personalised medicine. Recent publication of the ability of modern sequencing techniques to catalogue SNP data from a sample of B10 cells illustrates the power and sensitivity of sequencing technology.
The ability to detect the thousands of stable genetic differences that occur in the human population is impacting on nutritional sciences and as a result a new vision of the delivery of nutritional advice has emerged-personalised nutrition. Personalised nutrition, which parallels the concepts of personalised medicine and pharmacogenetics, encapsulates the idea that individuals vary in their nutrient metabolism and in their response to diet. Key features of the concept of personalised nutrition are that it is disease risk, not treatment, which varies between individuals and that risk is modulated by an interaction between genetics and nutrition. It is based on the premise that a diet which provides for optimal health and low disease risk in some individuals may not be effective in others.
It is well appreciated that individuals differ in their metabolic response to diet. For example, triglyceride responses to high-/lowfat diets differ between individuals and following current dietary guidelines can lead to alterations in blood lipid profiles in some people but not in others; the basis of such differences is regarded as being at least partly genetic. [3] [4] [5] Indeed, coronary heart disease (CHD) is associated with familial lipid disorders such as familial hypercholesterolaemia 6 and in clinical practice family history and subsequent testing for carriage of specific genetic variants are already being used before preventative treatment with diet, in combination with drug treatment. Thus, this is a form of personalised nutrition already in use. However, in recent years the term 'Personalised Nutrition' has been become associated with new genomic technologies and/or considering a wider number of genes and their variants, and applying the concept to risk and prevention of a wider range of diseases, and in particular to achieving 'optimal health'. Personalised nutrition takes an individualistic approach to many of today's medical challenges that are multifactorial in aetiology (for example, cardiovascular disease, cancer) with risk being modulated by nutritional, lifestyle, gender and potential genetic influences. 7 To develop effective personalised nutrition robust epidemiological, clinical and mechanistic information is needed on:
The specific genetic variants, both singly and in combination, that affect metabolism.
The extent to which these variants, together with intake of specific dietary components, affect risk of different diseases in different populations.
The mechanisms by which SNPs and nutrients affect disease aetiology.
LINKING GENETICS, NUTRITION AND DISEASE RISK
As illustrated schematically in Figure 2 , there are several key steps between SNP identification and 'individualising' nutritional requirements. Often genetic variants are functionally neutral and, therefore, as far as personalised nutrition is concerned the first step is to filter genetic information and focus attention on those SNPs that have been shown to have functional effects on nutrient metabolism. This focus also strengthens any associated epidemiological evidence relating to these SNPs and disease risk. As discussed below, numerous SNPs have now been reported to alter nutrient metabolism. Indeed, the metabolism of a nutrient can be affected by multiple SNPs in the same gene or in different genes within a metabolic pathway and this complicates any assessment of links between genetic factors and nutrition on metabolic outcomes. A further important factor is the potential modulation of genetic effects by nutritional intake.
Folate has a central role in the methylation cycle and the enzymes involved contain a number of well-characterised SNPs. Methylene tetrahydrofolate reductase contains a C677T polymorphism, which causes an alanine to valine amino-acid change. This SNP is the most common genetic factor associated with increased blood homocysteine and reduced folate concentrations, although methylene tetrahydrofolate reductase contains another variant, A1298C, which also affects the enzyme activity and interacts with the C677T polymorphism. 8, 9 Furthermore, the A66G variant in methionine synthetase reductase, another gene within the homocysteine-related metabolic pathway, has been reported to modulate the influence of the homozygous T variant in C677T, and evidence for further functional variants in genes that code for biochemically linked components of 1-carbon metabolic pathways indicates the need to assess genetic variation over the pathways as a whole. 8 The micronutrient selenium (Se) is incorporated in the body into 25 selenoproteins as the amino-acid selenocysteine. This requires a unique mechanism that involves a structure in the 3 0 -untranslated region (3 0 -UTR) of the selenoprotein mRNA and
Maybe I won't ask Yrgen to assess how my genes affect my disease risk? The assessment will make me worry and could affect my job, insurance, ….
The company Yrgen told me that my gene A may give me a higher chance of heart disease unless I take a folate supplement but more folate may affect my chances of getting cancers.
My gene B seems to protect against heart disease, especially if I eat less unsaturated fats. Wow, confusing! Figure 1 . Personalised nutrition in the future? The cartoon encapsulates the difficulties individuals would face in understanding the complexities of how diet and genetics influence health and in using personalised nutrigenomic information.
several specific-binding proteins. 10, 11 Several selenoprotein genes have now been shown to contain SNPs that are functionally relevant. 11, 12 The glutathione peroxidases (GPx1-4) have wellknown antioxidant functions and a SNP in GPX1 causes proline to leucine amino-acid change at codon 198 that lowers enzyme activity. 13 In vivo studies indicate that this variant modulates the response of GPx1 activity to Se intake.
14 Individuals TT or CC for rs713041, a SNP identified the 3 0 -UTR region of the GPX4 gene, 15 show different responses of lymphocyte GPx activities to Se supplementation. 16 Furthermore reporter gene, RNA-protein binding, and overexpression studies also indicate that T and C variants are functionally significant. 11, 16, 17 Selenoprotein P (SePP) accounts for B65% of plasma Se and has a transport role. 18 A variant in a TC repeat sequence within the SEPP1 promoter affects reporter activity in HepG2 cells. 19 A G/A variant within the 3 0 -UTR (rs7579) and a G/A variant that causes an alanine to threonine amino-acid change at codon 234 both modulate the response of various blood parameters of Se metabolism to Se supplementation 20 and both affect the relative proportion of SePP isoforms in plasma. 21 The data suggest that SNPs in SEPP1 affect Se availability for synthesis of other selenoproteins by modulating SePP capacity to transport Se. Selenoprotein S (SelS) functions in the unfolded protein response in the endoplasmic reticulum. 9 A SNP in the promoter of its gene affects levels of inflammatory markers such as tumour necrosis factor-alpha and interleukin1-beta. 22 The existence of multiple functionally relevant SNPs in selenoprotein genes shows that to understand how genetics affects requirements for Se requires assessment of combinations of the different SNPs and genetic variation over the pathway as a whole (Figure 3) .
Dietary carotenoids are converted to vitamin A by the enzyme b-carotene 15,15 0 -monoxygenase (BCMO1) in enterocytes. 23 A proportion of absorbed b-carotene is cleaved with the remainder leaving the intestine; variation in cleavage efficiency leads to high inter-individual variability of plasma levels of carotenoid-related metabolites. 24, 25 SNPs within BCMO1 have been identified 26 and purified recombinant protein with double-mutations corresponding to rs1293492 and rs7501331 show lower catalytic activity in vitro and homozygous females showing a lower ability to convert b-carotene in vivo. However, as described above for folate and Se metabolism, the story is complicated by other genetic variants, both within BCMO1 and in other genes. A GWAS identified variants in the region upstream of BCMO1 to be associated with plasma carotenoid levels 27 and these have been reported to also affect conversion efficiency in vivo when female volunteers were given a pharmacological dose of b-carotene. 28 Furthermore, SNPs in other genes involved in lipoprotein metabolism (for example, apolipoprotein A-IV, apolipoprotein B, lipoprotein lipase and hepatic lipase) and intracellular transport of fatty acids have also been reported to modulate plasma carotenoids status, indicating that carotenoid metabolism is affected by a range of multiple genetic factors. 29, 30 The above examples from folate, Se and carotenoid metabolism illustrate that genetic influences on nutrient metabolism are being identified but that the impact of SNPs is complex. As a result assessment of nutrient-gene interactions requires consideration of variants within and across nutrient-related pathways, not only single genes or single variants. 8, 11, 31 The links between SNPs, nutrition and disease risk are more tenuous. Many disease association studies adopt a hypothesis-based approach focused on looking for association of SNPs in genes linked to metabolism of a specific nutrient or pathway with disease susceptibility. Such studies are often relatively small in population size and although they require robust replication they have the advantage allowing examination of interactions between nutrient status and SNPs in specific target genes. Although numerous SNPs have been reported to be associated with altered disease risk, such focussed studies differ from several limitations: observed associations are often inconsistent between studies; supporting knowledge of the functional consequences of the variant is lacking; critically, key relevant variants could be missed. However, the usefulness of this candidate gene approach in providing evidence for the association of nutrient-related SNPs with disease risk, and its limitations, are illustrated by the examples below.
Low-serum folate and/or elevated homocysteine are considered risk factors for neural tube defects. 32, 33 As C677T in methylene tetrahydrofolate reductase affects folate metabolism, much attention has focussed on its role in risk of these defects. The overall picture is that C677T is associated with increased risk of neural tube defects in some populations (for example, Irish) but not all. 34 However, the effect of this variant on health seems Figure 3 . Complexity of genetic influences on the biological role of a nutrient, illustrated by Se metabolism. The scheme illustrates that dietary Se is incorporated into B25 selenoproteins, including the glutathione peroxidases (GPx) and selenoproteins H, P, S and W, by a specific mechanism involving recoding of the UGA codon to recognise a transfer RNA for the amino-acid selenocysteine, a structure (the SECIS) in the 3 0 -untranslated region (3 0 -UTR) of the mRNA and a number of RNA-binding proteins (0). Activity of the selenoproteins affects several related biochemical pathways. SNPs in genes which affect Se incorporation and selenoprotein synthesis can alter selenoprotein activity and thus the pattern of activity in the downstream biochemical pathways. The complexity of potential genetic effects arises from (1) genetic variants in multiple selenoprotein genes, (2) the possibility that effects on synthesis of one selenoprotein can affect synthesis of others and so alter the overall pattern of selenoprotein activity and (3) the effects of changes in selenoprotein activity on downstream pathways. Figure 2 . The steps from genetics to personalised nutritional requirements. The scheme illustrates the need to (1) focus on SNPs with known functional effects, (2) consider multiple variants within relevant biochemical pathways, (3) integrate both genetic and dietary information and (4) then relate both genetic and dietary factors to disease risk.
complex as the T variant, which appears to increase risk of neural tube defect and possibly cardiovascular disease, may decrease risk of bowel cancer if folate intake is high. 8, 9 Association studies of SNPs in selenoprotein genes and cancer risk provide only limited evidence that single SNPs alone are rarely found to reproducibly influence disease risk; an exception is the observation that a SNP in the promoter of SELS has been associated with colorectal cancer risk and replicated in a second population 35, 36 and with gastric cancer. 37 In addition, rs5859 SNP in the gene encoding the 15 kDa selenoprotein has been linked to prostate cancer risk 38 and using tagging SNP approaches SNPs in GPX2, GPX3 and GPX4 have been associated with rectal or colorectal cancer risk, 39 ,40 but these have not been replicated. Several studies suggest that selenoprotein SNPs, in combination with Se status or other variants, influence susceptibility to various cancers. For example, it appears that Se status impacts on the effect of genotype for rs5859 in SEP15 on lung cancer risk in smokers; lower lung cancer risk was associated with increased plasma Se concentration in AA individuals but with decreased Se status in people with GG and GA genotypes suggesting that Se supplementation would only benefit smokers who were AA genotype for this SNP. 41 In addition, the Pro198Leu polymorphism in GPX1 has been reported to modulate the relationship between plasma Se and prostate cancer risk. 42 The existence of multiple functionally relevant SNPs in selenoprotein genes that are possibly associated with disease risk shows that to understand how genetics affects requirements for a nutrient it is necessary to assess genetic variation over the nutrient 0 s metabolic pathways as a whole.
These observations highlight the importance of considering combinations of the different SNPs having interacting effects at a biological level due to the biochemical functions of the encoded proteins. For example, consider antioxidant protection. Plasma vitamin C levels are influenced by SNPs in the SLC23A1 gene that encodes the intestinal transporter responsible for uptake of the vitamin, but antioxidant defence mechanisms are also influenced by other SNPs, including a valine to alanine variation in the mitochondrial targeting sequence of manganese superoxide dismutase (rs4880 in SOD2) and SNPs in the selenoprotein genes. 43, 44 Interestingly, prostate cancer risk has been reported to be affected by an interaction between a SNP in SEPP1 and rs4880 in SOD2. 45 There is evidence that risk of both breast and prostate cancers are affected by the latter SNP but the results from different studies have been inconsistent. Interestingly, the effect of the SNP has been observed to be significantly modulated by antioxidant status 46, 47 and in some studies its influence on breast cancer risk was reported to be affected by fruit and vegetable intake indicating that it is likely that risk is modulated by a dietgene interaction. 47 In relation to lipid metabolism and CHD, genetic factors are clearly related to clinical metabolic disease; for example, it has been estimated that 450% of individuals with premature CHD have familial lipid disorders 6 and in addition familial hypercholesterolaemia, which is associated with increased risk of CHD, is associated with known SNPs in the low-density lipoprotein receptor and/or apolipoprotein B genes. However, the impact of other variants is still being explored. In the wider population, measures of cholesterol and lipoprotein metabolism are used as biomarkers of atherosclerosis risk and so are used as a basis of dietary advice. However, individual's responses are unpredictable. 5 Indeed there is an increasingly extensive literature on the effects of SNPs in lipid metabolism genes on blood biomarkers of CHD risk. 5 Two points that emerge from this work are that the impact of SNPs on both lipid metabolism and disease risk factors can be modulated by diet and that multiple SNPs can affect this complex metabolism. For example, in individuals who are GA or AA for the -75A/G SNP in the gene encoding apolipoprotein A1 increased polyunsaturated fat intake led to higher levels of high-density lipoprotein-cholesterol (HDL-C), but the opposite effect was found in GG individuals. 5 Similarly, in individuals CC for a SNP in the gene encoding hepatic lipase increased fat intake led to increased HDL-C, but in TT individuals there was a fall in HDL-C levels; furthermore, importantly there were also different effects depending on ethnicity. As HDL-C levels are often regarded as a biomarker for cardiovascular disease risk such findings suggest that the interaction between diet and these SNPs could be critical in determining disease risk. Levels of low-density lipoprotein-and HDL-cholesterol are dependent on other SNPs in addition to the two mentioned above and using an approach to assess variance across the lipid metabolism pathway a study of 93 SNPs in 13 lipid metabolism related genes found that the majority of the genetic variance in these phenotypic parameters was explained by haplotypes for these variants 48 and the contribution from SNPs in the different genes could be quantified.
In contrast to hypothesis-led candidate gene studies, GWAS have provided a hypothesis-free approach to identification of genetic influences on risk of a number of multifactorial diseases such as type-2 diabetes, heart disease and cancers. These large studies have identified sets of SNPs associated with the disease in question; these can be quite large with up to 40 variants linked to risk of type-2 diabetes, 49 47 for Crohn's disease and 71 for ulcerative colitis. 50 In general each risk allele has a relatively small effect, the cumulative effect of multiple variants has a significant effect on risk but the SNPs that emerge as having significant effects account for only a small proportion of the genetic contribution to disease risk; for example, for type 2 diabetes GWAS can account for 3-10% risk 49, 51 as opposed to estimates of up to 40% reported to be heritable. 52 Major limitations of GWAS are that it has been difficult to either (1) include nutritional or lifestyle factors into such analyses-either the nutritional status data, or the tools to incorporate them into a large genome-wide analysis, have not been available-or (2) assess combined effects of multiple variants. 53, 54 Importantly, analytical methods to incorporate environmental and nutritional data into GWAS studies, and to analyse multiple gene-gene interactions, are being developed 31, [53] [54] [55] and in the future it will be important to use these types of approaches to incorporate robust nutritional status data into GWAS. To obtain sufficient statistical power this will require data sets to be sufficiently compatible to be merged. 56 Further complexities in diet-SNP interactions include the possibility that a SNP may have a beneficial effect on risk of one disease but be detrimental to another (for example, folate 8 ) or that the impact of the SNP may vary with diet, as found for the effect of SNP in apolipoprotein A1 on HDL-cholesterol affected by polyunsaturated fat intake. 5 
STATUS AND FUTURE PERSPECTIVES
As illustrated in the previous sections, many SNPs have now been reported to influence either nutrient metabolism, processes linked to disease or biochemical risk factors of disease. It is also clear that the impact of genetic variation on nutritional metabolism and disease susceptibility is complex and that it is necessary to assess effects of multiple variants over whole nutrient-related pathways, not single genes or single variants, and then assess how these effects are influenced by nutritional factors. To date many variants have been catalogued and from these some nutritionally relevant SNPs with functional consequences and effects on metabolism identified-but, despite exceptions, in general we are still limited in our ability to define key interactions, genes and pathway effects on disease risk. However, this field of research is developing rapidly, with increasing numbers of SNPs proposed to be associated with disease risk or biomarkers of risk. For example, several SNPs are linked to familial hypercholesterolaemia and there are a significant number of reports of variants in lipoprotein metabolism affecting metabolic markers of risk of CHD; 5 although less thoroughly studied, an expanding number of SNPs in selenoprotein and antioxidant genes have been associated with risks of different cancers. 43, 57 However, many of these reported associations need to be confirmed and validated in different populations.
Major challenges lie in developing statistical and mathematical approaches for assessment of multiple genetic and dietary factors. It is encouraging that methods are becoming available both to combine and analyse large data sets in terms of metabolic pathways 31, [53] [54] [55] and to use mathematical modelling to quantify and predict effects of genetic variations, 31, 48, 58, 59 as has been used for example in the case of folate metabolism. 58 Interestingly, incorporation of multiple SNP data into a genetic risk score was found to be a useful in assessing CHD risk. 59 If personalised nutrition is to be developed, the scientific challenges are to obtain robust data on how genotype, in conjunction with nutrient intake, predicts disease risks, and to develop tools to quantify these complex interactions so that overall an individual can be allocated some form of 'nutrigenomic risk score' that is appropriate for clinical use by clinicians, biochemists or dieticians. Bioinformatic and statistical tools need to be further developed to integrate large data sets and take both genetic and diet effects into account in large and/or multiple populations, and then quantify and mathematically model the effects of both genetics and diet. Critically, robust measures of dietary intake are needed and here the development of appropriate high-throughput metabolomic assays may become increasingly relevant. 60, 61 In conclusion, there are not only many scientific challenges to be overcome before genotype information can be widely applied to dietary advice but also the use of genetic information in assessing disease risk raises multiple social and ethical issues. Key issues in personalised nutrition are the need for strong evidence of the robustness and validity of gene-diet-disease relationships and the acceptance of the concept by the public. Application of genome sequencing and nutrigenomics in a commercial setting is still a long way off. However, the use of genotype information that affects nutrient metabolism is becoming increasingly used to provide better refined or novel biomarkers of metabolism and disease risk. One can foresee knowledge increasing to a stage when genotype, combined with metabolomic measures that may both give dietary information and profile blood metabolites, 60, 61 could become part of an individual's metabolic 'signature' for use clinically in addition to those risk factors currently considered (see Figure 4 ). Quantifying and modelling multiple biomarkers in a systems biology approach may be a promising way ahead. Further knowledge of genetic effects on metabolic profiles and risk of multifactorial diseases, together with incorporation of a range of other biomarkers of disease risk should contribute to the 'personalisation' of advice for preventing these diseases, and so to the moving forward from the use of the responses to questions such as 'Is there history of this symptom/disease in your family?' to the use of available genome sequence and metabolomic data.
